ClinicalTrials.gg
SuspendedNCT04278768Updated Mar 19, 2026

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A Phase 1/2 interventional study of Emavusertib and Venetoclax in Acute Myelogenous Leukemia and Myelodysplastic Syndrome, sponsored by Curis, Inc.. Suspended at 32 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Curis, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was suspended
Dosing completed in all cohorts. Planning underway for potential additional patient cohorts.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
366
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Planned enrollment
69th of 1,907
366 · median 35
Started
2020
with 91 others
Phase 1/2
306 of 2,137
47 open now
Registered
1,656th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 69th largest by planned enrollment of the 1,907 interventional ones that give a count, is one of 92 that started in 2020, is one of 306 in phase 1/2, and was the 1,656th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 312 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS).

Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study:

  • Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor
  • R/R AML with spliceosome mutations of splicing factor 3B subunit 1 (SF3B1) or U2AF1
  • R/R hrMDS with spliceosome mutations of SF3B1 or U2 small nuclear RNA auxiliary factor 1 (U2AF1)
  • Number of pretreatments: 1 or 2

The Phase 2a Dose Expansion will be in 3 Cohorts of patients:

  1. R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor;
  2. R/R AML with spliceosome mutations of SF3B1 or U2AF1; and
  3. R/R hrMDS (Revised International Prognostic Scoring System [IPSS-R] score > 3.5) with spliceosome mutations of SF3B1 or U2AF1.

All patients above have had ≤ 2 lines of prior systemic anticancer treatment. In previous versions of this protocol there was a Phase 1b portion of the study, in which patients with AML or hrMDS received CA-4948 in combination with venetoclax. This part of the study is no longer open for enrollment.

Read the detailed description

The primary objective of the Phase 1 portion of the study is to determine the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D) for emavusertib in monotherapy in patients with AML, intermediate-2, high risk, or every high risk MDS based on the safety and tolerability, dose-limiting toxicities (DLTs), and Pharmacokinetic (PK)/Pharmacodynamic (PD) findings.

The primary objective of the Phase 1b portion of the study is to determine MTD and RP2D for emavusertib in combination with azacitidine (AZA) in treatment naïve patients with hrMDS or in combination with venetoclax (VEN) in R/R patients with AML or hrMDS after first line treatment based on the safety and tolerability, DLTs and PK and pharmacodynamic findings. Note, this portion of the study is no longer enrolling patients.

The primary objective of the Phase 2a portion of the study (emavusertib monotherapy expansion) is to assess anti-cancer activity of CA-4948 at the RP2D in patients with R/R AML with FMS-like tyrosine kinase-3 (FLT3) mutations, or patients with R/R hrMDS or R/R AML with spliceosome mutations of SF3B1 or U2AF1.

Emavusertib is formulated as tablets for twice daily oral administration. Each treatment cycle will be 28 days in length and repeated in the absence of toxicity. Patients who tolerate emavusertib may continue to receive emavusertib until progression of disease, intolerable toxicity, lack of clinical benefit, withdrawal from the trial, or study termination.

The emavusertib starting dose level will be 200 milligrams (mg) twice daily (BID) which was determined to be safe, capable of achieving relevant levels of drug exposure as well as demonstrating signs of biologic activity and clinical efficacy in an ongoing study (Study CA-4948-101). For phase 1, emavusertib is taken daily for 28 days of a 28 day cycle. For Phase 1b, emavusertib is taken daily for 21 days of a 28 day cycle in combination with venetoclax.

Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21 days of the 28-day Cycle. Second and subsequent cycles start with the target dose level.

In each of the Phase 1/1b cohorts, three patients with AML or MDS were enrolled at the designated dose. If none of the first 3 patients experience a DLT during the first cycle, patients may be enrolled into the next higher dose level. If 1 patient out of the first 3 experiences a DLT, the dose level may be expanded with an additional 3 patients. If 2 or 3 patients out of the first six experienced a DLT, this will be considered a DLT rate above the MTD (> 33%), and additional enrollment will proceed at a lower dose level. Any adverse reaction that led to dose reduction or discontinuation is considered a DLT unless the adverse reaction is clearly and solely related to disease.

The RP2D will be determined by the Clinical Safety Committee (CSC) in consultation with the Sponsor, considering all aspects of safety, tolerability, biologic activity, pharmacokinetics and preliminary efficacy in the trial population. The intent of the RP2D is to provide a dose and schedule that will maximize the opportunity for clinical benefit, while minimizing the risk of toxicity. The RP2D may be below the MTD. The CSC may request enrollment of additional patients at any previously-explored dose level in order to make an appropriate RP2D or MTD determination.

The expansion phase will begin once the RP2D from Phase 1 Dose Escalation phase has been identified. There will be 3 Cohorts and patients will be assigned to each Cohort based on baseline disease:

  1. R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor; or
  2. R/R AML with spliceosome mutations of SF3B1 or U2AF1; or
  3. R/R hrMDS (IPSS-R score > 3.5) with spliceosome mutations of SF3B1 or U2AF1

All patients have had ≤ 2 lines of prior systemic anticancer treatment. This part of the study is no longer open for enrollment.

03

Conditions studied

  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome

Keywords

  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • AML
  • MDS
  • Interleukin-1 receptor-associated kinase 4 (IRAK4)
  • FLT3-ITD or TKD mutant
  • FLT3 Wild Type (WT)
  • Relapse/refractory to hypomethylating agent (HMA)
  • spliceosome mutation
  • SF3B1
  • U2AF1
  • Serine/arginine-rich splicing factor 2 (SRSF2)
  • Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2 (ZRSR2)
  • higher-risk MDS
  • failing prior treatment
  • R/R AML or relapse/refractory AML
  • R/R hrMDS or relapse/refractory hrMDS
  • FLT3 mutation
  • FLT3 inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ≥18 years of age
  2. of at least 3 months
  3. (ECOG) Performance Status of ≤1
  4. Cytomorphology based confirmed diagnosis of MDS or AML (as per World Health Organisation [WHO] 2016 classification) with the following characteristics.

    Phase 1 Dose Escalation (Monotherapy)

    • AML (primary or secondary, including treatment-related) after failing at least 1 standard treatment (may include chemotherapy, re induction therapy or stem cell transplantation).

    OR

    • Higher-risk R/R MDS that are considered resistant/ following at least 2 to 3 cycles of hypomethylating agent (HMA) or evidence of early progression

    Phase 2a Dose Expansion (Monotherapy)

    Patients with:

    • R/R AMLwith FLT3 mutations who have been previously treated with a FLT3 inhibitor
    • R/R AML with spliceosome mutations of SF3B1 or U2AF1
    • R/R hrMDS (IPSS-R score > 3.5) with spliceosome mutations of SF3B1 or U2AF1
    • Number of prior treatments: 1 or 2
  5. Acceptable organ function at screening
  6. Ability to swallow and retain oral medications
  7. Negative serum pregnancy test in women of
  8. Women of childbearing potential and men who partner with a woman of childbearing potential must agree to use highly effective methods for the duration of the study and for 180 days after the last dose of emavusertib
  9. Willing and able to provide written and comply with the requirements of the trial
  10. Able to undergo serial bone marrow sampling and peripheral blood sampling

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with acute promyelocytic leukemia (APL, M3)
  2. Has known active central nervous system (CNS) leukemia
  3. hematopoietic stem cell transplant (Allo-HSCT) within 60 days of the first dose of emavusertib, or (GVHD) requiring ongoing up titration of medications prior to start of emavusertib
  4. Chronic myeloid leukemia (CML)
  5. Any prior systemic anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within 3 weeks (or 5 half-lives) prior to start of emavusertib.

    Localized radiation or surgical resection of skin cancers allowed.

  6. Use of any agent within 3 weeks or 5 half-lives, whichever is shorter, prior to start of emavusertib
  7. Presence of an acute or chronic toxicity resulting from prior anti-cancer therapy, with the exception of alopecia that has not resolved to Grade ≤ 1 within 7 days prior to start of emavusertib.
  8. Known allergy or to any component of the formulation of emavusertib
  9. Major surgery, other than diagnostic surgery, \<28 days from the start of emavusertib; minor surgery \<14 days from the start of emavusertib
  10. Patients with active advanced malignant solid tumors
  11. Known to be (HIV) positive or have an acquired immunodeficiency syndrome-related illness
  12. virus (HBV) deoxyribonucleic acid (DNA) positive or virus (HCV) infection \<6 months prior to start of emavusertib unless viral load is undetectable, or HCV with cirrhosis
  13. Uncontrolled or severe cardiovascular disease including myocardial infarction or unstable angina within 6 months prior to CA-4948, Class II or greater congestive heart failure, or \< 50% by echocardiogram or multi-gated acquisition scan, serious arrhythmias uncontrolled on treatment, clinically significant pericardial disease, cardiac amyloidosis, congenital long syndrome, or QTc with Fridericia's correction (QTcF) that is unmeasurable or > 450 milliseconds (msec) on Screening (ECG)
  14. Gastrointestinal disease or disorder that could interfere with the swallowing, oral absorption, or tolerance of emavusertib
  15. Pregnant or lactating
  16. Systemic fungal, bacterial, viral, or other infection that is not controlled
  17. Any other severe, acute, or chronic medical, psychiatric or social condition, or laboratory abnormality that may increase the risk of trial participation or emavusertib administration
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
366 participants (estimated)

Study arms

  • Experimental
    Emavusertib (CA-4948) dose escalation

    Patients receive emavusertib monotherapy BID daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Drug: Emavusertib

  • Experimental
    Emavusertib dose escalation + Venetoclax

    The starting dose for emavusertib will be 200 mg BID for 21 days of a 28-day Cycle. Anticipated emavusertib doses will be 200 and 300 mg BID. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.

    Drug: Venetoclax · Drug: Emavusertib

  • Experimental
    Emavusertib monotherapy dose expansion

    The Expansion phase will begin once the RP2D from Phase 1 Dose Escalation phase has been identified. There will be 3 Cohorts and patients will be assigned to each Cohort based on baseline disease.

    Drug: Emavusertib

Interventions

  • Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.

    Also known as: CA-4948

  • Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level. This arm of the study has been closed to enrollment.

  • Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.

    Also known as: CA-4948

06

What researchers measure

Primary outcomes

  1. Determine Maximum Tolerated Dose (MTD) of emavusertib (CA-4948) monotherapy (Phase 1)

    The highest dose at which there is \<33% Dose Limiting Toxicity rate in the first cycle of treatment in a minimum of 6 patients.

    Time frame: 28 days

  2. Determine the Recommended Phase 2 Dose (RP2D) of emavusertib monotherapy (Phase 1)

    The RP2D will be determined by the Clinical Safety Committee (CSC) in consultation with the Sponsor, considering all aspects of safety, tolerability, biologic activity, pharmacokinetics and preliminary efficacy in the trial population. The intent of an RP2D is to provide a dose and schedule that will maximize the opportunity for clinical benefit, while minimizing the risk of toxicity.

    Time frame: 24 months

  3. Determine Maximum Tolerated Dose (MTD) of emavusertib in combination with venetoclax (Phase 1b)

    The highest dose at which there is \<33% Dose Limiting Toxicity rate in the first cycle of treatment in a minimum of 6 patients.

    Time frame: 28 days

  4. Determine the Recommended Phase 2 Dose (RP2D) of emavusertib in combination with venetoclax (Phase 1b)

    The RP2D will be determined by the Clinical Safety Committee (CSC) in consultation with the Sponsor, considering all aspects of safety, tolerability, biologic activity, pharmacokinetics and preliminary efficacy in the trial population. The intent of an RP2D is to provide a dose and schedule that will maximize the opportunity for clinical benefit, while minimizing the risk of toxicity.

    Time frame: 24 months

  5. To assess anti-cancer activity (Phase 2a - AML patients)

    Proportion of patients who achieve complete response (CR) + complete response with partial hematological recovery (CRh)

    Time frame: 24 months

  6. To assess anti-cancer activity (Phase 2a - hrMDS patients)

    Overall response rate: proportion of patients who achieve CR+ partial response (PR)

    Time frame: 24 months

  7. To assess safety (Phase 1b)

    Clinical safety assessments including frequency of adverse events (AEs)

    Time frame: 24 months

Secondary outcomes

  1. To characterize the pharmacokinetic (PK) parameters of emavusertib measured by maximum plasma concentration (Cmax) (Phase 1 and 1b)

    maximum plasma concentration (Cmax)

    Time frame: 24 months

  2. To characterize the pharmacokinetic (PK) parameters of emavusertib measured by trough plasma concentration (Cmin) (Phase 1 and Phase 1b)

    trough plasma concentration (Cmin)

    Time frame: 24 months

  3. To characterize the pharmacokinetic (PK) parameters of emavusertib measured by Time to maximum plasma concentration (Tmax) (Phase 1 and 1b)

    Time to maximum plasma concentration

    Time frame: 24 months

  4. To characterize the pharmacokinetic (PK) parameters of emavusertib measured by Area under the plasma concentration versus time curve(AUC) [0-24] (Phase 1 and 1b)

    Area under the plasma concentration-time curve from 0 to 24 hours

    Time frame: 24 months

  5. To characterize the pharmacokinetic (PK) parameters of emavusertib measured by Area under the plasma concentration-time curve from 0 to infinity (AUC[INF]) (Phase 1 and 1b)

    Area under the plasma concentration-time curve from 0 to infinity

    Time frame: 24 months

  6. To characterize the pharmacokinetic (PK) parameters of emavusertib measured by Plasma terminal elimination half-life (T 1/2) (Phase 1 and 1b)

    Plasma terminal elimination half-life (T 1/2)

    Time frame: 24 months

  7. To assess clinical response (Phase 1 and 1b)

    For AML: assessed by proportion of patients who reach complete response (CR) + complete response with partial hematological recovery (CRh) assessed by proportion of patients who reach complete response with incomplete hematologic recovery (CRi) or CR or CRh For hrMDS: overall response rate of CR+partial response (PR)

    Time frame: 24 months

  8. To assess clinical response (Phase 1 and 1b)

    Assessed by transfusion independence

    Time frame: 24 months

  9. To assess tolerability and long term safety (Phase 2a)

    Clinical safety assessments including frequency of adverse events (AEs)

    Time frame: 24 months

  10. To assess clinical response (Phase 2a)

    For AML - assessed by proportion of patients who achieve CR or CRh or CRi; For hrMDS - assessed by proportion of patients who achieve CR or PR or marrow complete response (mCR)

    Time frame: 24 months

  11. To assess clinical response (Phase 2a)

    Assessed by duration of response (DOR)

    Time frame: 24 months

  12. To assess clinical response (Phase 2a)

    Assessed by time to response

    Time frame: 24 months

  13. To assess clinical response (Phase 2a)

    Assessed by transfusion independence

    Time frame: 24 months

  14. To assess clinical response (Phase 2a)

    Assessed by overall survival (OS)

    Time frame: 24 months

07

Study locations

32 sites
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Albert Einstein Medical College
    The Bronx, New York 10461, United States
  • Novant Health Hematology - Forsyth
    Winston-Salem, North Carolina 27103, United States
  • The Ohio State University Wexner Medical Center - James Cancer Hospital
    Columbus, Ohio 43210, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Vseobecna Fakultni nemocnice v Praze
    Prague, 12 808, Czechia
  • Service d'hématologie clinique CHU de Nice
    Nice, 6200, France
  • APHP - Sorbonne Universite
    Paris, 75012, France
  • APHP - Hopital Saint Louis
    Paris, 75475, France
  • Marien Hospital Dusseldorf; Klinik fur Onkologie und Hamatologie, Palliativmedizin
    Düsseldorf, 40479, Germany
  • Universitätsklinikum Hamburg-Eppendorf (UKE)
    Hamburg, 20246, Germany
  • Universitatsklinikum Leipzig; Medizinische Klinik und Poliklinik I
    Leipzig, 04103, Germany
  • Klinikum rechts der Isar der Technischen Universitat Munchen
    München, 81675, Germany
  • Universitatsklinikum Munster
    Münster, 48149, Germany
  • Soroka University MC
    Beersheba, 84100, Israel
  • Edith Wolfson Medical Center
    Holon, 5822012, Israel
  • Hadassah University MC
    Jerusalem, 9112001, Israel
  • Azienda Ospedaliera Santa Croce e Carle
    Cuneo, Italy
  • Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
    Meldola, Italy
  • Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
    Gdansk, 80-214, Poland
  • University Hospital in Krakow
    Krakow, 31 501, Poland
  • Hospital de la Santa Creu I Sant Pau (Neuvo Hospital)
    Barcelona, Spain
  • Hospital Universitaro del a Princesa
    Madrid, 28006, Spain
  • MD Anderson Cancer Center Madrid
    Madrid, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2020 (actual). Primary completion is estimated for Apr 2026, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2020
First posted
Feb 20, 2020
StartActual
Jul 6, 2020
Primary completionEst.
Apr 1, 2026
CompletionEst.
Apr 1, 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04278768
Lead sponsor
Curis, Inc.
Responsible party
Sponsor
First posted
Feb 20, 2020
Start date
Jul 6, 2020
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Mar 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CA-4948

Start the discussion